All products sold on this website are research-grade materials intended exclusively for laboratory research use by qualified professionals and are not approved for human or veterinary use.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Third-party-indexed research abstracts for the compounds in the catalog. Each abstract summarises what published in‑vitro and animal-model research investigates — written in third person, no dosing guidance, no therapeutic claims. Every citation resolves to a PubMed identifier.
Research on BPC-157, a synthetic pentadecapeptide derived from a sequence in human gastric juice, investigates its activity in rodent connective-tissue injury models. Published rat studies examine tendon-to-bone reattachment after Achilles detachment, muscle-crush trauma, and corticosteroid-impaired muscle recovery, reporting effects on collagen organisation, edema, and macroscopic injury markers. The pentadecapeptide is described in the literature as stable in gastric juice, which underpins much of the in-vivo work characterising its tissue-repair pharmacology.
References
Research on BPC-157, a synthetic pentadecapeptide derived from a sequence in human gastric juice, investigates its activity in rodent connective-tissue injury models. Published rat studies examine tendon-to-bone reattachment after Achilles detachment, muscle-crush trauma, and corticosteroid-impaired muscle recovery, reporting effects on collagen organisation, edema, and macroscopic injury markers. The pentadecapeptide is described in the literature as stable in gastric juice, which underpins much of the in-vivo work characterising its tissue-repair pharmacology.
References
Research on thymosin β4 (TB4), of which TB-500 is described in the literature as the active fragment, examines a 43-residue actin-sequestering peptide that is released by platelets at sites of injury. Preclinical work in rodent models investigates its role in angiogenesis, dermal wound closure, hair-follicle development, and cardiac repair. The cited studies characterise effects on cell migration, blood-vessel formation, and inflammatory chemokine expression in animal and cell-culture systems.
References
This blend pairs BPC-157, a synthetic pentadecapeptide derived from human gastric juice, with TB-500, described in the literature as a thymosin β4-derived fragment. Independent preclinical research on BPC-157 in rat models examines tendon, ligament, and muscle injury endpoints, while research on thymosin β4 investigates dermal wound closure, angiogenesis, and cell migration in animal and cell-culture systems. Studies of the two peptides as a combination preparation are limited; the cited literature concerns the constituent compounds individually.
References
This blend combines modified GRF(1-29) — the no-DAC CJC-1295 species — with ipamorelin, a selective pentapeptide growth-hormone secretagogue. Foundational research on the CJC-1295 albumin-conjugate platform in rat anterior pituitary cells investigates GRF-receptor activation and in-vitro stability, while research on ipamorelin in rat pituitary cultures and pentobarbital-anaesthetised rats characterises its potency and selectivity at the GHS-R1a receptor relative to GHRP-6. The two peptides are studied as complementary research tools for examining somatotroph signalling.
References
Research on CJC-1295 with DAC investigates a modified GRF(1-29) sequence conjugated to a maleimido Drug Affinity Complex that binds covalently to serum albumin, extending plasma residence. Preclinical work in rat anterior pituitary cells characterises the bioconjugate's activation of the GRF receptor and in-vitro stability, and animal studies in GHRH-knockout mice examine the compound's effects on growth parameters and the GH/IGF-1 axis. The cited research concerns mechanism of action and pharmacokinetics in non-clinical systems.
References
Research on the modified GRF(1-29) sequence — the no-DAC form of CJC-1295 — investigates a 30-amino-acid analogue of human GHRH carrying substitutions that increase resistance to dipeptidyl peptidase-IV cleavage. Studies in cultured rat anterior pituitary cells characterise the parent sequence's binding at the GRF receptor and its capacity to stimulate GH secretion in vitro. Animal-model work in GHRH-knockout mice further examines the unconjugated and bioconjugate forms in the context of GH-axis activation.
References
Research on ipamorelin investigates a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective growth-hormone secretagogue at the GHS-R1a receptor. In-vitro work in primary rat pituitary cell cultures characterises its potency and efficacy in releasing GH relative to GHRP-6, and in-vivo studies in pentobarbital-anaesthetised rats examine its dose–response profile and selectivity for the GH axis without concurrent stimulation of ACTH, cortisol, or prolactin.
References
Research on sermorelin investigates a 29-amino-acid N-terminal fragment of human growth-hormone-releasing hormone (GHRH 1-29) that retains the bioactivity of the parent hormone. Preclinical literature characterises the sequence as a GHRH-receptor agonist on anterior-pituitary somatotrophs that acts through cAMP-mediated signalling to elicit pulsatile GH release. Comparative pharmacological studies in rats examine the relative bioactivity of GHRH(1-29) and its agonist analogues at the somatotroph receptor.
References
Research on tesamorelin investigates a synthetic analogue of human GHRH carrying a trans-3-hexenoyl modification at the N-terminal tyrosine. Non-clinical pharmacology work characterises the modification as conferring resistance to dipeptidyl peptidase-IV degradation, with the peptide showing slowed in-vitro proteolysis in rat, dog, and human plasma compared with native GRF(1-44)NH2 and prolonged plasma elimination kinetics in animal models.
References
This blend combines tesamorelin — a hexenoyl-modified GHRH analogue characterised in non-clinical pharmacology studies as resistant to dipeptidyl peptidase-IV degradation — with ipamorelin, a selective pentapeptide growth-hormone secretagogue acting at the GHS-R1a receptor. Independent preclinical research on each peptide examines GH-axis pharmacology in rat plasma, rat pituitary cell cultures, and rodent models. Combination-specific studies are limited; the cited literature concerns the constituent compounds individually.
References
Research on GHK-Cu investigates a copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a sequence present in human plasma and in collagen. In-vitro studies in dermal-fibroblast cultures characterise its stimulation of collagen and glycosaminoglycan synthesis at picomolar-to-nanomolar concentrations. Gene-expression analyses in human cell systems further examine the tripeptide-copper complex's modulation of pathways related to tissue remodelling, antioxidant defence, and extracellular-matrix turnover.
References
This blend combines the GHK-Cu copper tripeptide with BPC-157, a pentadecapeptide derived from a sequence in human gastric juice, and TB-500, the active fragment of thymosin β4. Independent preclinical literature characterises GHK-Cu's effects on collagen and glycosaminoglycan synthesis in fibroblast cultures, BPC-157's activity in rat connective-tissue injury models, and thymosin β4's role in cell migration, angiogenesis, and dermal repair in rodent systems. Combination studies are not established; the cited research concerns the constituent compounds individually.
References
This multi-peptide research preparation combines GHK-Cu, the KPV tripeptide fragment of α-MSH, BPC-157, and TB-500. Independent preclinical literature investigates GHK-Cu's stimulation of collagen synthesis in fibroblast cultures, KPV's anti-inflammatory activity and NF-κB pathway modulation in murine colitis models, BPC-157's effects in rat connective-tissue injury models, and thymosin β4's role in angiogenesis and dermal repair. Studies of the four-peptide blend are not established; the cited research concerns the constituent peptides individually.
References
Research on KPV (Lys-Pro-Val) investigates the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone. In-vitro studies characterise its inhibition of NF-κB activation and pro-inflammatory cytokine signalling, and in-vivo work in murine colitis models examines its uptake via the PepT1 di/tripeptide transporter and effects on intestinal inflammation in DSS- and TNBS-induced disease. Subsequent animal studies further investigate the PepT1/KPV axis in the context of colitis-associated tumour development.
References
Research on LL-37 investigates the 37-residue cathelicidin-derived antimicrobial peptide processed from the human hCAP-18 precursor in neutrophils. Foundational molecular work characterises the FALL39/CAMP gene and the proteolytic generation of mature LL-37 in granulocytes. Biophysical studies in lipid-bilayer and micelle systems further examine the peptide's amphipathic α-helical conformation, membrane orientation, and its mechanism of bacterial-membrane disruption.
References
Research on thymosin α-1 investigates a 28-residue acetylated thymic peptide originally isolated from calf thymus and characterised by amino-acid sequence analysis. Mechanistic work in murine and human cell systems examines the peptide's activation of Toll-like receptor signalling on dendritic cells and its role in T-cell maturation and cytokine responses. Cited studies focus on the molecular characterisation and immunological pharmacology of the peptide.
References
Research on epitalon investigates the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), a sequence derived from work on the pineal-gland extract epithalamin. In-vitro studies in human somatic cell lines examine its induction of telomerase activity and effects on telomere length. Animal-model work in female outbred SHR mice characterises its influence on biomarkers of aging, lifespan distribution, and spontaneous tumour incidence including a reported reduction in leukemia frequency relative to saline-treated controls.
References
Research on pinealon investigates the synthetic tripeptide Glu-Asp-Arg (EDR) developed by the Khavinson research group. In-vitro studies in cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells examine its dose-dependent suppression of reactive-oxygen-species accumulation under oxidative stress and its association with ERK 1/2 signalling and cell-cycle modulation. Animal-model work in pregnant rats further investigates the tripeptide's effects on offspring outcomes in a model of prenatal hyperhomocysteinemia.
References
Research on AOD-9604 investigates a modified C-terminal fragment of human growth hormone (hGH 177-191) carrying an N-terminal tyrosine addition. Preclinical studies in C57BL/6J (ob/ob) obese mice and in β3-adrenergic receptor knockout mice characterise the fragment's effects on body-weight gain, adipose-tissue mass, lipogenesis, and β3-AR mRNA expression following chronic intraperitoneal administration, with the fragment investigated as a non-receptor-binding lipolytic domain of GH.
References
Research on MOTS-c investigates a 16-residue peptide encoded within the mitochondrial 12S rRNA region. Mechanistic work in cultured cells and in mouse models characterises the peptide's targeting of skeletal muscle, its inhibition of the folate cycle and de-novo purine biosynthesis, and downstream AMPK activation. In-vivo studies in mice further examine its effects in age- and high-fat-diet-related insulin resistance and diet-induced obesity models.
References
Research on bremelanotide (PT-141) investigates a cyclic heptapeptide analogue of α-MSH that acts as an agonist at central melanocortin receptors, including MC3R and MC4R. Animal-model work in rats characterises systemic administration's activation of hypothalamic neurons measured by c-Fos immunoreactivity, and a PNAS-published study in female rats examines the peptide's selective facilitation of solicitational behaviours independent of lordosis or general locomotor activity.
References
Research on kisspeptin-10 investigates the C-terminal decapeptide (Kp-10) of kisspeptin, the endogenous ligand of the G-protein-coupled receptor GPR54 (KISS1R). Animal-model and cell work characterises Kp-10's direct stimulation of GnRH neurons in mouse hypothalamus and the GPR54-dependent release of GnRH into cerebrospinal fluid with parallel LH rises in sheep. Subsequent rat studies further examine kisspeptin signalling in the arcuate nucleus and its role in pulse-generator regulation of the reproductive axis.
References
Research on selank investigates the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, an analogue of the immunomodulator tuftsin developed at the Russian Institute of Molecular Genetics. In-vivo work in rats characterises the peptide's intranasal regulation of BDNF mRNA and protein expression in the hippocampus. Transcriptomic studies further examine selank's modulation of hippocampal and spleen gene expression following single and chronic administration, with reported changes in plasma-membrane-associated transcripts.
References
Research on semax investigates the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, an analogue of the ACTH(4-10) fragment lacking corticotropic activity. In-vivo work in rats characterises the peptide's regulation of BDNF and TrkB expression in the hippocampus following intranasal administration, with reported increases in BDNF protein and exon-III BDNF mRNA. Additional gene-expression studies in rat brain further examine neurotrophin pathway modulation by the peptide.
References
Research on cerebrolysin investigates a mixture of low-molecular-weight neuropeptides and free amino acids generated by standardised enzymatic breakdown of lipid-free porcine brain proteins. In-vitro studies in primary cultured chicken neurons characterise the preparation's protection of the cytoskeletal protein MAP2 under stress. In-vivo work in rat models of focal cerebral ischemia further examines its effects on subventricular-zone neural-progenitor proliferation, doublecortin-positive neuroblast migration, and functional recovery after embolic middle-cerebral-artery occlusion.
References
Research on nicotinamide adenine dinucleotide (NAD+) and its precursors investigates a coenzyme central to redox reactions, sirtuin signalling, and mitochondrial function. Animal-model work in aged mice characterises the effects of NAD+ repletion via nicotinamide riboside on mitochondrial unfolded-protein response, muscle stem-cell function, and lifespan distribution. Long-term studies in mice further examine oral nicotinamide mononucleotide administration in the context of age-associated physiological decline, energy metabolism, and insulin sensitivity.
References
Research on nicotinamide adenine dinucleotide (NAD+) and its precursors investigates a coenzyme central to redox reactions, sirtuin signalling, and mitochondrial function. Animal-model work in aged mice characterises the effects of NAD+ repletion via nicotinamide riboside on mitochondrial unfolded-protein response, muscle stem-cell function, and lifespan distribution. Long-term studies in mice further examine oral nicotinamide mononucleotide administration in the context of age-associated physiological decline, energy metabolism, and insulin sensitivity.
References
Research on glutathione (γ-Glu-Cys-Gly, GSH) investigates the most abundant non-protein thiol in mammalian tissues and a central component of cellular antioxidant defence. Foundational biochemistry work characterises the two-enzyme biosynthetic pathway involving glutamate-cysteine ligase and glutathione synthase, the GSH:GSSG redox couple, and selective pharmacological modification of glutathione metabolism. Review work in hepatocyte and tissue systems further examines transcriptional regulation of GCLC and the role of cysteine availability as the rate-limiting precursor.
References